Postpartum Haemorrhage

Overview & Definition

Obstetric haemorrhage remains the single largest direct cause of maternal death worldwide, killing more than 80,000 women every year, the overwhelming majority in low- and middle-income settings where access to skilled birth attendance, blood and surgical theatres is limited.[1] Within this category, postpartum haemorrhage (PPH) — bleeding from the genital tract after delivery — is the dominant event, and it is one of the few emergencies in medicine where a previously well young woman can die within an hour of delivery if the response is slow or disorganised. The physiological reserve of pregnancy (a 40% expansion of blood volume to roughly 5–6 L and a hyperdynamic circulation) means that tachycardia and hypotension are late signs; by the time the blood pressure falls, a woman may already have lost more than a quarter of her circulating volume. The clinical art of PPH is therefore to act on blood loss and signs before the body decompensates, and to run resuscitation and definitive treatment in parallel rather than in sequence.

Primary PPH is excessive bleeding from the genital tract occurring within 24 hours of delivery (the "third" and "fourth" stage of labour); the trial literature defines it as a blood loss of 500 mL or more after birth.[5] Loss of 1000 mL or more is classified as severe PPH and sets the escalation threshold in the landmark trials.[3] In practice, any loss with haemodynamic compromise needs the full PPH response regardless of the millilitres measured, because young pregnant women compensate until blood loss is substantial.

Secondary PPH (also called late or delayed PPH) is abnormal or excessive bleeding occurring from 24 hours up to 12 weeks postpartum. It is far less dramatic than primary PPH but is an important cause of readmission; the typical causes are retained products of conception, puerperal endometritis, and subinvolution of the placental bed, with rare but serious contributors such as uterine arteriovenous malformation or choriocarcinoma.[1]

PPH severity grading should drive the level of response, and the modern approach anchors the response to early detection plus a bundled treatment rather than to a volume alone: delays in the detection or treatment of PPH cause complications and death, and objective measurement with a first-response bundle more than halved the composite severe outcome in the E-MOTIVE trial.[3]

[2] [3] [12] [11]

Classification — the 4 Ts

The causes of PPH are organised into the 4 Ts, a mnemonic that doubles as a bedside checklist because the first action after resuscitation is to identify which "T" is bleeding.[1][4]

[4] [4]

The percentages are a teaching heuristic rather than a precise audit — cohort studies show atony accounts for 60–80%, trauma 15–25%, tissue 5–10%, and thrombin around 1% (often under-recognised until laboratory clotting returns).[4] More than one T may operate simultaneously: a woman with severe pre-eclampsia who delivers by emergency caesarean can have atony (from a overdistended, magnesium-relaxed uterus), surgical bleeding from the hysterotomy (trauma), and evolving DIC (thrombin) all at once.

Epidemiology & Risk Factors

PPH is the leading cause of maternal death worldwide and, even with routine prophylactic uterotonics, remains a common complication causing about one-quarter of all maternal deaths globally.[5] The burden and case fatality are greatest where blood, theatre and referral systems are limited, which is why protocolised early detection and bundled treatment matter most in those settings.[3]

Risk factors should be identified at booking and again on admission in labour, because 40% of PPH occurs in women with an identifiable antenatal risk factor and a further group are identifiable intrapartum — but a clinically important fraction (around 20%) occur in women with no risk factor at all, which is why every birth attendant must be drilled in the response.[1][4]

[4]

Pathophysiology

Normal postpartum haemostasis depends on a myometrial mechanism unique to pregnancy. The uterus is supplied by the uterine and ovarian arteries, whose terminal branches — the spiral (coiled) arteries of the endometrium — course through and are surrounded by the interlacing oblique myometrial fibres. When the placenta separates, these spiral arteries are sheared open; the only way they are closed is by myometrial contraction physically compressing them. The classical description, taught for over a century, is that the myometrium acts as "living ligatures" — the muscle fibres are the tourniquet. No clot, however strong, will hold against an open spiral artery if the uterus around it is flaccid. This is why uterine atony is the dominant cause of PPH, and why the entire uterotonic armamentarium is built to make the muscle contract. [4]

The three pillars of physiological third-stage haemostasis are therefore: (1) a strong myometrial contraction, (2) a competent clotting system, and (3) a complete, empty uterus. Each pillar maps to a "T": failure of contraction is Tone, retained placental tissue that prevents retraction is Tissue, and a failure of clotting is Thrombin. Trauma (the second T) bypasses all three by physically tearing vessels that muscle and clot cannot reach. [4]

Why atony happens. The myometrium becomes exhausted or relaxes when it is overstretched (twins, macrosomia, polyhydramnios), exhausted (prolonged labour, chorioamnionitis), structurally abnormal (fibroids, congenital anomaly), pharmacologically relaxed (magnesium sulphate, volatile anaesthetics, nifedipine, nitroglycerin, prolonged oxytocin with receptor down-regulation) or anatomically unable to contract around a retained placenta. Once the uterus fills with blood it becomes further distended and further atonic — a vicious cycle that the bimanual "rub up the fundus" is designed to break. [4]

Coagulopathy and DIC. Pregnancy raises fibrinogen well above non-pregnant levels, and that reserve is a key defence against bleeding: in a prospective cohort of women with PPH, fibrinogen was the only haemostasis marker independently associated with progression to severe PPH — risk 2.63-fold higher for each 1 g/L decrease, with a concentration of 2 g/L or below carrying a 100% positive predictive value for severe PPH (and a value over 4 g/L a 79% negative predictive value).[13] DIC in obstetrics is almost always secondary — to placental abruption, pre-eclampsia/HELLP, retained intrauterine fetal death, amniotic fluid embolism, sepsis, or massive haemorrhage itself (consumption + dilution). The laboratory signature is low fibrinogen, prolonged PT/APTT, low platelets, and high D-dimer; clinically it presents as oozing from IV cannula sites, gums and the surgical field.

The fibrinolytic balance and why tranexamic acid works. Clot formation is only half of the haemostatic story; the other half is whether the clot is allowed to persist. Plasminogen is converted to plasmin, which digests fibrin (fibrinolysis) and dissolves the clot. In the hyper-fibrinolytic state that accompanies massive obstetric bleeding, clots are lysed almost as fast as they form — particularly in the richly plasminogen-activator-rich placental bed. Tranexamic acid is a lysine analogue that blocks the binding of plasminogen to fibrin, preventing its activation to plasmin and thereby stabilising the clot. This is the mechanistic rationale for the WOMAN trial finding that early TXA reduces death from bleeding.[2] Timing matters: the mortality benefit was greatest when treatment began within 3 h of birth, and the trial concluded TXA should be given as soon as possible after bleeding onset.

The lethal triad of massive haemorrhage. Sustained blood loss drives three interlocking derangements that each worsen the others: hypothermia (heat lost with shed blood and cold crystalloid), acidosis (poor perfusion → lactate), and coagulopathy (consumption, dilution with crystalloid, and hypothermia-driven platelet and clotting-factor dysfunction). Once the triad is established, clotting fails and bleeding accelerates independent of the original cause — which is why warmed fluids, early blood product replacement in a balanced ratio, and rapid source control are non-negotiable in major PPH.[4]

Shock physiology in PPH. Pregnancy physiology masks early blood loss — the young pregnant myocardium compensates remarkably, so a "normal" blood pressure can hide a substantial loss, and falling blood pressure in PPH is a late, dangerous sign. Tachycardia, narrowed pulse pressure, anxiety and air-hunger come first and should trigger the full protocol, not observation: delays in the detection or treatment of PPH result in complications or death.[3]

Clinical Presentation

PPH is a clinical diagnosis made at the bedside — there is no test that should delay the call for help. The classical presentation is sudden heavy vaginal bleeding after delivery, but three caveats dominate exam stems and real life.[1]

First, clinical estimation of visible loss is inaccurate and under-recognises larger volumes; blood is soaked into drapes, sheets, the chux pad, and pooling behind the mother. Objective measurement with a calibrated blood-collection drape (the E-MOTIVE approach) provides earlier, more accurate diagnosis.[3] Second, bleeding may be concealed — retained behind a closed cervix or in a distended, atonic uterus, with only a trickle visible externally while a large volume accumulates internally. Third, shock may be out of proportion to visible loss for exactly this reason.

Recognising the depth of shock is what drives the speed and scale of the response. The standard ATLS-style haemorrhagic shock classes translate to a term pregnant woman (blood volume ~5 L) as below — but the cardinal point is that class I and II are the PPH danger zone: a woman who is mildly tachycardic with a narrowed pulse pressure is already in class II and needs the full protocol, not "observation".[1]

[3]

Atypical and deceptive presentations examiners test deliberately. The grand multipara with concealed intrauterine bleeding who looks deceptively well. The woman on therapeutic low-molecular-weight heparin who oozes from every puncture site. The caesarean section where bleeding is intra-abdominal (broad ligament haematoma) and the only clue is falling haemoglobin and rising girth. The amniotic fluid embolism presenting as sudden cardiovascular collapse and DIC in the immediate postpartum period. The uterine inversion causing shock disproportionate to bleeding, with a fleshy mass at the cervix/vagina. [4]

Differential Diagnosis

In practice the differential is the 4 Ts, because the bleeding source is almost always within the genital tract. But the discriminators — what distinguishes each T at the bedside — are what the examiner is testing. Three or more should be reproduced with their distinguishing feature.[4]

[4]

The cannot-miss mimics are amniotic fluid embolism (sudden collapse, hypoxia, DIC — an anaesthetic, not obstetric, bleed in origin) and uterine rupture in the scarred uterus; both need an immediate surgical/anaesthetic response. [4]

Clinical & Bedside Assessment

The first assessment is simultaneous with resuscitation and takes less than two minutes. The team leader performs a focused examination while another team member secures the airway, two large-bore cannulae and oxygen. [8]

[3]

Named signs and manoeuvres. Bimanual uterine compression (the "rub up the fundus"): one hand massages the fundus abdominally through the abdominal wall while the other fist is placed in the anterior fornix (or the whole hand in the vagina) compressing the lower segment against the body of the uterus — both stimulates contraction and directly tamponades the uterine vessels. Uterine balloon tamponade tests the cavity and treats atony. The "4 Ts" rapid screen (fundus, placenta, perineum/cervix, clotting) is the bedside analogue of the diagnostic framework. Visual loss estimation is now supplemented by calibrated drape collection (E-MOTIVE), which detected PPH in 93.1% versus 51.1% of cases when paired with the treatment bundle.[3]

Quantifying loss. The E-MOTIVE trial established that objective blood-loss measurement with a calibrated drape plus a first-response treatment bundle (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, escalation) reduced a composite of severe PPH, laparotomy for bleeding, or death from bleeding from 4.3% with usual care to 1.6% — a risk ratio of 0.40.[3] This bundle-and-drape approach is now reshaping practice globally.

Investigations

Do NOT delay treatment for investigations. Treat while drawing blood.[1]

[13] [3]

The fibrinogen trend during active PPH is the single most useful laboratory number: fibrinogen was the only marker associated with severe PPH in cohort data — risk 2.63-fold higher per 1 g/L fall, and a concentration of 2 g/L or below positively predicted severe PPH in every case — so a falling fibrinogen should trigger aggressive product support (cryoprecipitate or fibrinogen concentrate) and escalation.[13]

Management — Resuscitation

PPH management is a drill, not a thought process. The objective in the first minutes is to buy time — secure the airway, fill the circulation, raise the haematocrit, stop the fibrinolysis — while a second work-stream identifies and treats the cause. These run in parallel, not in series.[1][8]

[3] [2]

Management — Definitive & Stepwise (by the 4 Ts)

Definitive management is cause-specific. The generic rule is to work through the 4 Ts in order, treating whatever you find; most cases declare themselves within the first 5 minutes. [4]

Tone — uterine atony (70%)

The uterotonic ladder is applied sequentially while continuing resuscitation; trial evidence supports oxytocin first-line, with misoprostol 800 µg sublingual the best-studied alternative, and notes that evidence for ergometrine and injectable prostaglandins remains limited.[5][10]

[5] [10] [14] [5] [10] [14]

Why oxytocin first? The Cochrane treatment review found oxytocin infusion more effective than misoprostol with fewer side-effects as first-line therapy, while acknowledging the evidence base is small and offers no randomised evidence on commonly used agents such as injectable prostaglandins, ergometrine, and Syntometrine.[5][10] For prevention, the network meta-analysis of 196 trials (135,559 women) found the three highest-ranked agents for PPH of 500 mL or more were ergometrine plus oxytocin, misoprostol plus oxytocin, and carbetocin — but both combination regimens carried significantly more side-effects, and carbetocin may be more effective than oxytocin without an increase in side-effects.[6]

Escalation — mechanical and surgical management of refractory atony

When the uterotonic ladder has been exhausted and the uterus is still atonic, escalation proceeds through a recognised ladder. The objective is to stop the bleeding while preserving the uterus wherever possible — peripartum hysterectomy is a morbidity-dense, fertility-ending last resort. [4]

[11]

The decision to abandon conservative measures is clinical: a woman in uncontrolled haemorrhage with deranged coagulation who is not responding should move to definitive surgery — the biggest mistake in PPH surgery is delaying the definitive life-saving operation, while remembering that randomised evidence on balloon tamponade is conflicting and observational success rates are high.[11]

Trauma (20%)

Traumatic bleeding is surgical. Once the uterus is confirmed firm and the placenta complete, examine the vagina, cervix and perineum under good light, in theatre, with adequate analgesia/anaesthesia. Bleeding points are clipped, ligated and repaired; high vaginal and cervical tears are sutured with absorbable sutures (the upper third of the vagina and cervix may require theatre and an experienced operator). Uterine rupture needs immediate laparotomy and repair (± hysterectomy depending on extent and parity). Uterine inversion must be replaced immediately (Johnson or O'Sullivan manoeuvre — reposition by lifting the uterus through the cervix with the whole hand, often after a uterine relaxant such as terbutaline/nitroglycerin) before giving uterotonics — giving a uterotonic to an inverted uterus traps the inversion. [4]

Tissue (9%)

Examine the placenta meticulously at every delivery: missing cotyledons, torn membranes, and vessels running to the edge (suggesting a succenturiate lobe) all indicate retained tissue. If the placenta is retained beyond 30 minutes, or if retained products are suspected, perform controlled cord traction (with uterotonic); if that fails, manual removal under anaesthesia in theatre with inspection and evacuation of the cavity.[1] In secondary PPH with suspicion of retained products, ultrasound-guided evacuation is the procedure of choice. Abnormal placentation (accreta/increta/percreta) is an increasingly common cause of catastrophic PPH (rising with caesarean rates) and usually needs a planned multidisciplinary approach with conservative surgery, balloon occlusion, or caesarean hysterectomy.

Thrombin (1%)

[13] [2]

The widely used massive transfusion protocol delivers blood products in a fixed ratio approximating 1 : 1 : 1 (RBC : FFP : platelets) to avoid the lethal triad of hypothermia, acidosis and dilutional coagulopathy. Viscoelastic testing (ROTEM/TEG) tailors replacement in real time. [4]

Specific Subtypes & Scenarios

Secondary PPH

Bleeding from 24 hours to 12 weeks postpartum. The three classic causes:[1]

PPH at caesarean section

Heavier intraoperative blood loss at caesarean section meets the PPH definition and triggers the same protocol. Specific causes include the uterine incision extending into the broad ligament or uterine artery, placenta praevia/accreta spectrum (catastrophic bleeding — anticipate and plan), and atony. Have oxytocin running on delivery of the baby, inspect the angles of the hysterotomy, and apply immediate bimanual compression; balloon tamponade and compression sutures can be placed at the time of laparotomy — balloon success is lower after caesarean (81.7%) than vaginal birth.[11]

PPH with placenta accreta spectrum

With rising caesarean rates, placenta accreta/increta/percreta is the modern obstetric emergency. Risk: previous caesarean + placenta praevia (risk up to 3% after one, over 60% after four scars). Diagnose antenatally on ultrasound/MRI; plan delivery at 34–36 weeks in a centre of excellence with multidisciplinary input, cell salvage, interventional radiology (prophylactic internal iliac balloon), and consent for caesarean hysterectomy. [4]

Complications & Pitfalls

PPH carries the full morbidity of massive haemorrhage plus several obstetric-specific complications.[1]

• Haemorrhagic shock and death — the endpoint if untreated; maternal death from PPH is a sentinel event. [1]
• Sheehan syndrome — anterior pituitary infarction following profound hypovolaemic shock during PPH (the pituitary is uniquely vulnerable in pregnancy due to a low-flow portal system in an enlarged, vascular gland). Presents as failure to lactate (low prolactin — the earliest sign), then amenorrhoea (low FSH/LH), hypothyroidism (low TSH — fatigue, cold intolerance), and adrenal insufficiency (low ACTH — fatigue, hypotension, hypoglycaemia). Requires lifelong hormone replacement. Now rare in high-resource settings but still seen where PPH is late-resuscitated.
• Acute kidney injury — from prolonged hypotension (acute tubular necrosis); usually reversible but cortical necrosis can occur.
• DIC and coagulopathy — consumption + dilution; worsens the bleeding cycle.
• Transfusion-related harm — TRALI, TACO, transfusion-transmitted infection, alloimmunisation.
• Surgical morbidity — peripartum hysterectomy (infertility), bladder/ureteric injury during ligation/hysterectomy, internal iliac artery ligation rarely causes lower-limb ischaemia.
• Psychological morbidity — PTSD, birth trauma, postnatal depression; ICU admission is itself a risk.
• Recurrence — 10–15% recurrence in next pregnancy; flag for future care.

Prognosis & Disposition

With prompt, protocolised management, the vast majority of women recover fully and leave hospital in 2–4 days. Prognosis is determined by the cause (atony responds to uterotonics; accreta is life-threatening), the time to control (death is a function of uncontrolled haemorrhage time), the reserve of the mother (anaemia, pre-existing disease worsen outcome) and the system (blood and theatre availability). [4]

Disposition: after major PPH, monitor on HDU/ICU for 12–24 h (continued bleeding, coagulopathy, fluid balance, renal function, signs of DIC). Iron replacement (oral or IV ferric carboxymaltose) for postpartum anaemia. Counsel about recurrence and the need for active management of the third stage in future pregnancies, with senior input and crossmatched blood available. Critical-incident review and debrief of every major PPH is mandatory (national maternal death/morbidity surveillance standards). [1]

Special Populations

Jehovah's Witnesses refuse transfusion of major blood components on religious grounds, and the obstetric team must plan for this antenatally, not in a crisis. The acceptable tools are cell salvage (with a continuous circuit, which many Witnesses accept as long as the blood remains in continuity with the body), tranexamic acid, oxytocin, iron and erythropoietin optimisation in the third trimester, and minimising phlebotomy. Document the woman's specific choices in a signed advance directive; arrange multidisciplinary counselling; and accept that mortality from major PPH is markedly higher in this group. Elective caesarean hysterectomy may be discussed in accreta. [8]

Women on anticoagulants (therapeutic LMWH for VTE, warfarin for a mechanical valve, or aspirin/heparin for inherited thrombophilia) bleed from every puncture and suture site. Stop or omit the anticoagulant where possible, reverse per haematology protocol (vitamin K and prothrombin complex concentrate for warfarin, protamine for heparin), give tranexamic acid early, plan delivery around anticoagulant timing, and consult haematology early. [2]

Women with inherited bleeding disorders — most commonly von Willebrand disease (the commonest inherited bleeding disorder) and haemophilia carriers — need a coordinated haematology-obstetric plan from booking. Have von Willebrand factor / factor VIII concentrate (or DDAVP where appropriate) available, give third-stage oxytocin mandatorily, and avoid regional anaesthesia only when factor levels are uncorrected. Mild vWD in pregnancy often normalises due to the physiological rise in vWF, but postpartum the levels fall and bleeding may occur days later. [4]

Low-resource and community settings — where theatre, anaesthesia, blood and even electricity are unavailable — demand a pragmatic, evidence-based approach. The E-MOTIVE first-response bundle (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, and escalation) is designed exactly for such settings and can run without blood-bank dependence.[3] Misoprostol is the heat-stable uterotonic of choice where an oxytocin cold chain cannot be guaranteed, and it can be administered by trained community health workers. Early referral before decompensation — and a functioning ambulance/referral chain — is the single biggest determinant of survival.

Previous PPH carries a 10–15% recurrence risk and demands an individualised plan: deliver in a unit with on-site blood and theatre, senior obstetrician present at delivery, active third-stage management with oxytocin, group-and-save on admission (crossmatch if high risk), large-bore IV access, and a low threshold to escalate to uterotonics, balloon and theatre. The single biggest predictor of recurrence is the severity of the index PPH.[1]

Advanced maternal age and grand multiparity (para 5 or more) — the atony risk rises with parity from cumulative myometrial damage and reduced muscle fibre concentration relative to fibrous tissue, and age adds independent vascular and comorbidity risk. These women deserve the same individualised approach as a previous-PPH woman. [4]

Evidence, Guidelines & Regional Differences

[2] [3]

Controversies and uncertainties. Several questions remain live. The optimal timing and dose of tranexamic acid beyond the first 3 h is unclear — late TXA shows no benefit, possibly harm, in subgroup analyses. Whether carbetocin (a long-acting oxytocin analogue) should replace oxytocin for prophylaxis is being settled by the heat-stable carbetocin programme, which addresses cold-chain failure in low-resource settings without yet showing superior efficacy in head-to-head trials. The place of fibrinogen concentrate versus cryoprecipitate is unsettled — concentrate is faster and smaller-volume but expensive. Viscoelastic (ROTEM/TEG)-guided transfusion is gaining ground over fixed-ratio protocols but needs equipment and expertise. The cell-salvage in obstetrics debate (theoretical amniotic fluid embolism risk) is largely resolved in favour of use, with leucocyte depletion filters. Finally, recombinant factor VIIa remains a last-resort, off-label, "before-hysterectomy" rescue with case-series support only.[4]

Prevention — Active Management of the Third Stage

Prevention outperforms treatment. Active management of the third stage of labour (AMTSL) reduced severe primary PPH (over 1000 mL) with an average RR 0.34 (very low certainty) and probably reduces primary blood loss over 500 mL and the use of therapeutic uterotonics.[12] The components:

1. Prophylactic uterotonic — the current WHO recommendation is oxytocin 10 IU IM or IV for all births; carbetocin may be more effective without more side-effects, and ergometrine-oxytocin adds efficacy at the cost of significant side-effects.[6]
2. Controlled cord traction with counter-traction on the suprapubic uterus, once the uterus is contracted and placenta separated.
3. Uterine massage after placental delivery.

For women at high risk (previous PPH, anaemia, coagulopathy, abnormal placentation, prolonged labour, instrumental delivery): ensure blood crossmatched, two IV cannulae, senior staff present, active third stage, and a low threshold to escalate. [12]

Exam Pearls & High-Yield Minutiae

[2]

Frequently misremembered facts (corrected): [5]

• Ergometrine is the one to avoid in hypertension/pre-eclampsia (NOT carboprost). Carboprost is the one to avoid in asthma — life-threatening bronchospasm after IM carboprost is documented.[14]
• Misoprostol treatment dose is 800 µg sublingual — the randomised dose; oxytocin infusion remains first-line.[10]
• Tranexamic acid 1 g IV reduces death from bleeding, especially within 3 h of birth — give as soon as possible, do not wait.[2]
• Active management of the third stage reduces severe PPH (over 1000 mL) with RR 0.34 — not a fixed "60%".[12]
• Sheehan syndrome is anterior pituitary necrosis — failure to lactate is the first sign.
• Spiral arteries are the living ligatures compressed by myometrial contraction.
• Fibrinogen is the laboratory number that matters: 2 g/L or below positively predicted severe PPH in every case in cohort data.[13]
• B-Lynch suture is a compression (brace) suture, not a ligation.

Complications Recap & When to Escalate

Exam application bank (NEET-PG / INICET)

One-line answer

Postpartum haemorrhage (PPH) = blood loss over 500 mL after birth within 24 h (primary); loss over 1000 mL is severe PPH. Secondary PPH = 24 h to 12 weeks postpartum. 4 Ts, with Tone (uterine atony) the dominant cause. Resuscitate and treat the cause in parallel. Uterotonics: oxytocin first-line, misoprostol 800 µg sublingual as alternative, then tranexamic acid 1 g IV (WOMAN). Mechanical/surgical: uterine balloon tamponade, compression sutures, artery ligation, hysterectomy (last resort).[5][2]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard.[5]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes.[5]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change.[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each.[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory.[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Postpartum Haemorrhage.

References

1. [1]Vogel JP, Williams M, Gallos I, et al. WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ global health, 2019.PMID 31139461
2. [2]WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet, 2017.PMID 28456509
3. [3]Gallos I, Devall A, Martin J, et al.; E-MOTIVE Collaborators. Randomized trial of early detection and treatment of postpartum hemorrhage (E-MOTIVE). N Engl J Med, 2023.PMID 37158447
4. [4]Escobar MF, Nassar AH, Theron G, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet, 2022.PMID 35297039
5. [5]Parry Smith WR, Papadopoulou A, Thomas E, et al. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev, 2020.PMID 33232518
6. [6]Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev, 2018.PMID 30569545
7. [7]Dahlke JD, Mendez-Figueroa H, Maggio L, et al. Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines. Am J Obstet Gynecol, 2015.PMID 25731692
8. [8]Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage (Green-top Guideline No. 52). BJOG, 2017.PMID 27981719
9. [9]Williams EV, Bolaji R, Mortimer A, et al. A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial. Nat Med, 2024.PMID 38844798
10. [10]Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev, 2014.PMID 24523225
11. [11]Suarez S, Conde-Agudelo A, Borovac-Pinheiro A, et al. Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis. Am J Obstet Gynecol, 2020.PMID 31917139
12. [12]Begley CM, Gyte GML, Devane D, McGuire W, Weeks AD, Biesty LM. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev, 2019.PMID 30754073
13. [13]Charbit B, Mandelbrot L, Samain E, et al.; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost, 2007.PMID 17087729
14. [14]Harber CR, Levy DM, Chidambaram S, Macpherson MB. Life-threatening bronchospasm after intramuscular carboprost for postpartum haemorrhage. BJOG, 2007.PMID 17261125